基于circRNA的AntimiR疗法:一种新的高血压治疗方法
Vahideh Tarhriz1,2, Kamran Hosseini3, Leila Abkhooie4,5
1Cardiovascular Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA.
Non-coding RNA research
|June 9, 2025
概括
新型非编码RNAs,包括抗miRs和循环RNAs (circRNAs),通过向氨酸 - 血管新生素系统 (RAS) 来治疗初级高血压,显示出有前途. 需要进一步的研究,以克服这些创新疗法的交付和安全挑战.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 心血管医学 心血管医学
背景情况:
- 目前的高血压治疗缺乏特异性和长期坚持.
- 初级和基本高血压需要新的,基于机制的治疗策略.
- 非编码RNAs (ncRNAs) 为治疗慢性疾病提供了新的途径.
研究的目的:
- 通过氨酸-血管新生素系统 (RAS) 调节,审查circRNA-microRNA相互作用在高血压中的作用.
- 探索抗miRs和circRNAs对高血压的治疗潜力和挑战.
- 突出基于ncRNA的疗法在心血管疾病的精密医学的进步.
主要方法:
- 对高血压中circRNA-miRNA相互作用的综合文献综述.
- 对针对RAS的ncRNA机制的分析.
- 基于ncRNA的策略的治疗优势和翻译挑战的评估.
主要成果:
- circRNAs和antimiRs可以调节RAS,为高血压管理提供潜力.
- 这些ncRNAs为初级和基本高血压提供了创新的治疗方法.
- 关键的挑战包括交付效率,非目标效应和安全问题.
结论:
- 环RNA-miRNA相互作用代表了高血压的有前途的治疗标.
- 克服交付和安全障碍对于ncRNA疗法的临床转化至关重要.
- 基于ncRNA的治疗方法可以推进高血压和心血管疾病的精准医学.
更多相关视频
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
144
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
144
Hypertension IV: Drug Therapy and Lifestyle Modifications
3
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
3
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
395
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
395
Antihypertensive Drugs: Direct Renin Inhibitors
506
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
506
Antihypertensive Drugs: Action of Diuretics
627
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
627
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
462
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
462


